相似文献
1
Cancer antigen 125 levels in inflammatory bowel diseases.炎症性肠病中的癌抗原125水平。
J Clin Lab Anal. 2009;23(4):244-8. doi: 10.1002/jcla.20323.
2
Ulcerative colitis, Crohn's disease, and irritable bowel syndrome have different profiles of extracellular matrix turnover, which also reflects disease activity in Crohn's disease.溃疡性结肠炎、克罗恩病和肠易激综合征具有不同的细胞外基质周转情况，这也反映了克罗恩病的疾病活动度。
PLoS One. 2017 Oct 13;12(10):e0185855. doi: 10.1371/journal.pone.0185855. eCollection 2017.
3
[Inflammatory bowel disease in children--an analysis of the clinical symptoms and selected biochemical parameters].[儿童炎症性肠病——临床症状及部分生化指标分析]
Med Wieku Rozwoj. 2007 Oct-Dec;11(4):401-7.
4
Serum beta 2-microglobulin as a biomarker in inflammatory bowel disease.血清β2-微球蛋白作为炎症性肠病的生物标志物
World J Gastroenterol. 2014 Aug 21;20(31):10916-20. doi: 10.3748/wjg.v20.i31.10916.
5
Serum galectins as potential biomarkers of inflammatory bowel diseases.血清半乳糖凝集素可作为炎症性肠病的潜在生物标志物。
PLoS One. 2020 Jan 13;15(1):e0227306. doi: 10.1371/journal.pone.0227306. eCollection 2020.
6
Circulating levels of chemerin and adiponectin are higher in ulcerative colitis and chemerin is elevated in Crohn's disease.循环中 chemerin 和脂联素的水平在溃疡性结肠炎中较高，而 chemerin 在克罗恩病中升高。
Inflamm Bowel Dis. 2010 Apr;16(4):630-7. doi: 10.1002/ibd.21091.
7
The utility of apoptosis inhibitor of macrophages as a possible diagnostic marker in patients with Crohn's disease.巨噬细胞凋亡抑制剂作为克罗恩病患者一种可能诊断标志物的效用。
BMC Gastroenterol. 2017 Mar 11;17(1):40. doi: 10.1186/s12876-017-0591-z.
8
Serum Serotonin Differentiates Between Disease Activity States in Crohn's Patients.血清 5-羟色胺可区分克罗恩病患者的疾病活动状态。
Inflamm Bowel Dis. 2020 Sep 18;26(10):1607-1618. doi: 10.1093/ibd/izaa208.
9
Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.非侵入性评估在监测炎症性肠病活动中的疗效：中国的一项前瞻性研究。
World J Gastroenterol. 2017 Dec 14;23(46):8235-8247. doi: 10.3748/wjg.v23.i46.8235.
10
Red cell distribution width for assessment of activity of inflammatory bowel disease.用于评估炎症性肠病活动度的红细胞分布宽度
Dig Dis Sci. 2009 Apr;54(4):842-7. doi: 10.1007/s10620-008-0436-2. Epub 2008 Aug 21.
引用本文的文献
1
Validation of an In Vitro Diagnostic Test for Endometriosis: Impact of Confounding Medical Conditions and Lesion Location.验证一种用于子宫内膜异位症的体外诊断测试：混杂医疗条件和病变位置的影响。
Int J Mol Sci. 2024 Jul 12;25(14):7667. doi: 10.3390/ijms25147667.
2
Molecular Management of High-Grade Serous Ovarian Carcinoma.高级别浆液性卵巢癌的分子管理
Int J Mol Sci. 2022 Nov 9;23(22):13777. doi: 10.3390/ijms232213777.
3
Management of the Adnexal Mass: Considerations for the Family Medicine Physician.附件肿物的管理：家庭医学医生的考量因素
Front Med (Lausanne). 2022 Jul 5;9:913549. doi: 10.3389/fmed.2022.913549. eCollection 2022.
4
Early Postnatal Comprehensive Biomarkers Cannot Identify Extremely Preterm Infants at Risk of Developing Necrotizing Enterocolitis.出生后早期综合生物标志物无法识别有发生坏死性小肠结肠炎风险的极早产儿。
Front Pediatr. 2021 Oct 22;9:755437. doi: 10.3389/fped.2021.755437. eCollection 2021.
5
Development and validation a simple model for identify malignant ascites.开发并验证一种简单的模型用于识别恶性腹水。
Int J Med Sci. 2021 Mar 3;18(9):1966-1974. doi: 10.7150/ijms.53743. eCollection 2021.
6
Chronic Medical Conditions and CA125 Levels among Women without Ovarian Cancer.慢性疾病与卵巢癌阴性女性的 CA125 水平。
Cancer Epidemiol Biomarkers Prev. 2018 Dec;27(12):1483-1490. doi: 10.1158/1055-9965.EPI-18-0203. Epub 2018 Sep 20.
7
Clinical laboratory and imaging evidence for effectiveness of agarose-agarose macrobeads containing stem-like cells derived from a mouse renal adenocarcinoma cell population (RMBs) in treatment-resistant, advanced metastatic colorectal cancer: Evaluation of a biological-systems approach to cancer therapy (U.S. FDA IND-BB 10091; NCT 02046174, NCT 01053013).含源自小鼠肾腺癌细胞群（RMBs）的干细胞样细胞的琼脂糖-琼脂糖大珠在治疗抵抗性晚期转移性结直肠癌中有效性的临床实验室及影像学证据：癌症治疗生物学系统方法的评估（美国食品药品监督管理局研究性新药申请-生物制品许可申请10091；临床试验注册号NCT 02046174，NCT 01053013）
Chin J Cancer Res. 2018 Feb;30(1):72-83. doi: 10.21147/j.issn.1000-9604.2018.01.08.
8
Correlates of the preoperative level of CA125 at presentation of ovarian cancer.卵巢癌患者就诊时 CA125 的术前水平相关因素。
Gynecol Oncol. 2010 Dec;119(3):462-8. doi: 10.1016/j.ygyno.2010.08.028. Epub 2010 Sep 17.
本文引用的文献
1
Review of fecal biomarkers in inflammatory bowel disease.炎症性肠病中粪便生物标志物的综述。
Dis Colon Rectum. 2008 Aug;51(8):1283-91. doi: 10.1007/s10350-008-9310-8. Epub 2008 Jun 10.
2
Serum carbohydrate antigen 125 levels in advanced heart failure: relation to B-type natriuretic peptide and left atrial volume.晚期心力衰竭患者血清糖类抗原125水平：与B型利钠肽及左心房容积的关系
Eur J Heart Fail. 2008 Jun;10(6):556-9. doi: 10.1016/j.ejheart.2008.04.012. Epub 2008 May 23.
3
Current and future diagnostic approaches: from serologies to imaging.当前及未来的诊断方法：从血清学检查到影像学检查。
Curr Gastroenterol Rep. 2007 Dec;9(6):489-96. doi: 10.1007/s11894-007-0065-5.
4
Cancer antigen 125 and prognosis.癌抗原125与预后
Curr Opin Obstet Gynecol. 2008 Feb;20(1):4-8. doi: 10.1097/GCO.0b013e3282f2b124.
5
Fecal levels of leukocyte markers reflect disease activity in patients with ulcerative colitis.溃疡性结肠炎患者粪便中的白细胞标志物水平反映疾病活动情况。
Scand J Clin Lab Invest. 2007;67(8):810-20. doi: 10.1080/00365510701452838.
6
Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.炎症性肠病中肠道炎症评估的非侵入性标志物：粪便乳铁蛋白、钙卫蛋白、PMN弹性蛋白酶、CRP及临床指标的表现
Am J Gastroenterol. 2008 Jan;103(1):162-9. doi: 10.1111/j.1572-0241.2007.01556.x. Epub 2007 Oct 4.
7
New players in the cytokine orchestra of inflammatory bowel disease.炎症性肠病细胞因子“乐团”中的新成员。
Inflamm Bowel Dis. 2007 Nov;13(11):1419-23. doi: 10.1002/ibd.20212.
8
Molecular pathogenesis of inflammatory bowel disease: genotypes, phenotypes and personalized medicine.炎症性肠病的分子发病机制：基因型、表型与个性化医疗。
Ann Med. 2007;39(3):177-99. doi: 10.1080/07853890701197615.
9
Immune dysfunction in inflammatory bowel disease.炎症性肠病中的免疫功能障碍。
Transl Res. 2007 Apr;149(4):173-86. doi: 10.1016/j.trsl.2006.11.009.
10
CA125: megadaltons of novel opportunities.CA125：大量新的机遇
Gynecol Oncol. 2007 Mar;104(3):505-7. doi: 10.1016/j.ygyno.2007.01.035.
Zotero 插件